Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sibrafiban.

M Dooley1, K L Goa

  • 1Adis International Limited, Auckland, Mairangi Bay, New Zealand. demail@adis.co.nz

Drugs
|April 3, 1999
PubMed
Summary
This summary is machine-generated.

Sibrafiban, a glycoprotein IIb/IIIa receptor antagonist, shows dose-dependent platelet inhibition in patients post-cardiac events. Ongoing trials compare its efficacy and bleeding risk against aspirin for secondary cardiac event prevention.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Challenges of Tacrolimus for Maintenance Immunosuppression Post-Lung Transplantation.

Transplantation proceedings·2017
Same author

Morphological appearance of uterine cavity on ultrasound prior to development of intrauterine adhesions.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2017
Same author

Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

CNS drugs·2016
Same author

Timely initiation of chemotherapy: a systematic literature review of six priority cancers - results and recommendations for clinical practice.

Internal medicine journal·2016
Same author

The impact of the introduction of an acute sedation practice guideline.

Acta neuropsychiatrica·2016
Same author

Sport, exercise and the menstrual cycle: where is the research?

British journal of sports medicine·2016
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • Sibrafiban is an oral, nonpeptide, double-prodrug of Ro 44-3888, a selective glycoprotein IIb/IIIa receptor antagonist.
  • It is being investigated for secondary prevention of cardiac events in patients stabilized after acute coronary syndromes.

Purpose of the Study:

  • To evaluate the dose-dependent inhibition of platelet aggregation by sibrafiban.
  • To compare the efficacy and safety of sibrafiban with aspirin in preventing cardiac events in high-risk patients.

Main Methods:

  • Phase II dose-finding study (TIMI 12) assessed platelet aggregation and plasma drug concentrations.
  • Phase III studies (SYMPHONY and 2nd SYMPHONY) compare sibrafiban to aspirin in patients post-myocardial infarction or unstable angina.

Related Experiment Videos

Main Results:

  • A dose-dependent inhibition of platelet aggregation was observed, correlating with plasma drug levels.
  • The most frequent adverse event associated with sibrafiban is bleeding, with minor hemorrhages occurring more often than with aspirin.

Conclusions:

  • Sibrafiban demonstrates pharmacodynamic activity relevant to secondary cardiac event prevention.
  • Further large-scale trials are ongoing to establish its clinical benefit and safety profile compared to aspirin.